We next sought to assess the molecular signature of BM CD8+ T cells from patients with MDS and AML secondary to MDS at the single-cell level to further identify the molecular signatures in specific CD8+ T-cell subpopulations associated with disease progression and clinical outcomes of AZA monotherapy. This evidence concerns the gene CD8A and myelodysplastic syndrome.